Robert is President of Foundation BioVentures LLC, which he uses as a vehicle to advise development-stage companies on corporate strategy and fundraising. Most recently, Bob was President and CEO of PhaseRx, a Seattle-based biotech where he raised over $75M through private/public financings/corporate partnerships, and sold the assets of the company to Roivant in 2018. Prior to PhaseRx, Bob was a General Partner with Frazier Healthcare Ventures, where he participated in raising over $600M in venture funds and invested over $60M in private venture-backed companies. Bob joined Immunex in 1984, where he built and led R&D programs in cell and molecular biology, and developed the first HIV gene therapy trial in the world, which led to the formation of the Immunex spinout Targeted Genetics. Bob has served on numerous corporate boards, including Array Biopharma (Nasdaq: ARRY) and XenoPort (Nasdaq: XNPT) and PhaseRx (Nasdaq: PZRX).He holds a Ph.D. in Biochemistry from University of London and a BS in Biological Sciences from the University of Newcastle-upon-Tyne.
Bob also has a passion for helping homeless youth and has been involved with YouthCare, a Seattle non-profit that helps homeless children transition off the streets and into educational, vocational and transitional housing opportunities, as a board member since 2005 and as Chairman from 2007-2010.